Impact of the perioperative inotropic support in grown-up congenital heart patients undergoing cardiac surgery: a propensity score adjusted analysis

[1]  K. Anstrom,et al.  Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. , 2020, The Journal of thoracic and cardiovascular surgery.

[2]  D. De Backer,et al.  Minimizing catecholamines and optimizing perfusion , 2019, Critical Care.

[3]  Timothy M. Koponen,et al.  Vasoactive‐inotropic score and the prediction of morbidity and mortality after cardiac surgery , 2019, British journal of anaesthesia.

[4]  S. Zakynthinos,et al.  Weaning failure of cardiovascular origin: how to suspect, detect and treat—a review of the literature , 2019, Annals of Intensive Care.

[5]  M. Girardis,et al.  Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper , 2018, Journal of cardiovascular pharmacology.

[6]  J. Dearani,et al.  Vasopressor magnitude predicts poor outcome in adults with congenital heart disease after cardiac surgery , 2018, Congenital heart disease.

[7]  P. Ponikowski,et al.  Treatments targeting inotropy. , 2018, European heart journal.

[8]  J. Nielsen-Kudsk,et al.  Levosimendan in pulmonary hypertension and right heart failure , 2018, Pulmonary circulation.

[9]  C. Torp‐Pedersen,et al.  Intraoperative milrinone versus dobutamine in cardiac surgery patients: a retrospective cohort study on mortality , 2018, Critical Care.

[10]  B. Cholley,et al.  Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice , 2017, Journal of cardiovascular pharmacology.

[11]  G. Veldtman,et al.  Morbidity After Cardiac Surgery in Patients With Adult Congenital Heart Disease in Comparison With Acquired Disease. , 2017, Heart, lung & circulation.

[12]  S. Scolletta,et al.  Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis , 2017, Critical Care.

[13]  Yaqing Ma,et al.  Efficacy and safety of levosimendan in patients with acute right heart failure: A meta‐analysis , 2017, Life sciences.

[14]  G. Chatellier,et al.  Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial , 2017, Journal of the American Medical Association (JAMA).

[15]  D. Faraoni,et al.  Outcomes and Costs of Cardiac Surgery in Adults with Congenital Heart Disease , 2017, Pediatric Cardiology.

[16]  R. Bellomo,et al.  Levosimendan for Hemodynamic Support after Cardiac Surgery , 2017, The New England journal of medicine.

[17]  K. Anstrom,et al.  Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery , 2017, The New England journal of medicine.

[18]  O. Tutarel,et al.  Contemporary cardiac surgery for adults with congenital heart disease , 2017, Heart.

[19]  M. Kirov,et al.  Low-Cardiac-Output Syndrome After Cardiac Surgery. , 2017, Journal of cardiothoracic and vascular anesthesia.

[20]  M. Pinsky.  The right ventricle: interaction with the pulmonary circulation , 2016, Critical Care.

[21]  J. Roos‐Hesselink,et al.  Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. , 2016, European heart journal.

[22]  G. Biondi-Zoccai,et al.  The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. , 2015, British journal of anaesthesia.

[23]  A. Marelli,et al.  Heart failure in adult congenital heart disease: Emerging concepts with a focus on tetralogy of Fallot. , 2015, Trends in cardiovascular medicine.

[24]  R. Mehta,et al.  Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. , 2015, International journal of cardiology.

[25]  S. Ringgaard,et al.  Acute Effects of Levosimendan in Experimental Models of Right Ventricular Hypertrophy and Failure , 2014, Pulmonary circulation.

[26]  R. Arnold,et al.  Right Ventricular Failure and Pathobiology in Patients with Congenital Heart Disease – Implications for Long-Term Follow-Up , 2013, Front. Pediatr..

[27]  U. Angadi,et al.  Is levosimendan effective in paediatric heart failure and post-cardiac surgeries? , 2013, Interactive Cardiovascular and Thoracic Surgery.

[28]  A. Redington,et al.  The failing right ventricle in congenital heart disease. , 2013, The Canadian journal of cardiology.

[29]  D. Stegeman,et al.  The calcium sensitizer levosimendan improves human diaphragm function. , 2012, American journal of respiratory and critical care medicine.

[30]  P. Cogo,et al.  Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial , 2012, Intensive Care Medicine.

[31]  M. Dünser,et al.  Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study , 2012, Intensive Care Medicine.

[32]  P. Kannankeril,et al.  Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias. , 2011, The American journal of cardiology.

[33]  H. Schaff,et al.  Risk factors and early outcomes of multiple reoperations in adults with congenital heart disease. , 2011, The Annals of thoracic surgery.

[34]  A. Poncelet,et al.  Congenital Cardiac Surgery : A Randomized , Double-Blind Clinical Trial , 2011 .

[35]  P. Dekhuijzen,et al.  Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure , 2011, British journal of pharmacology.

[36]  R. Abella,et al.  Morbidity and mortality risk factors in adults with congenital heart disease undergoing cardiac reoperations. , 2009, The Annals of thoracic surgery.

[37]  P. Kirshbom,et al.  One thousand repeat sternotomies for congenital cardiac surgery: risk factors for reentry injury. , 2009, The Annals of thoracic surgery.

[38]  J. Roos‐Hesselink,et al.  Seventeen years of adult congenital heart surgery: a single centre experience. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[39]  L. Heunks,et al.  Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[40]  M. Štěrba,et al.  Prospective observational study of levosimendan and weaning of difficult-to-wean ventilator dependent intensive care patients. , 2008, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[41]  R. Fryer,et al.  Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. , 2008, American journal of physiology. Heart and circulatory physiology.

[42]  J. Mynard,et al.  Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass , 2007, Critical care medicine.

[43]  G. Stellin,et al.  Risk of surgery for congenital heart disease in the adult: a multicentered European study. , 2007, The Annals of thoracic surgery.

[44]  M. Bonten,et al.  Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability , 2004, Intensive Care Medicine.

[45]  D. Nelson,et al.  Efficacy and Safety of Milrinone in Preventing Low Cardiac Output Syndrome in Infants and Children After Corrective Surgery for Congenital Heart Disease , 2003, Circulation.

[46]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[47]  E. Bayer,et al.  An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. , 2002 .